The reverse glucosamine sulfate pathway: application in knee osteoarthritis

Bibliography

• FELSON DT, LAWRENCE RC, DIEPPE PA et al.: Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann. Intern. Med. (2000) 133(8):635-646.
   PubMed Web of Science ®Google Scholar
• PELLETIER JP: Etiopathogenesis of osteoarthritis. In: Arthritis and Allied Conditions. JK W (Ed.) Lippincott Williams & Wilkins, Philadelphia, PA (2001):1969-1984.
   Google Scholar
• ALVAREZ-SORIA MA, LARGO R, SANTILLANA J et al.: Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann. Rheum. Dis. (2006) 65(8):998-1005.
   PubMed Web of Science ®Google Scholar
• PELLETIER JP, MARTEL-PELLETIER J, ABRAMSON SB: Osteoarthritis, an inflammatory disease. Potential implication for the selection of new therapeutic targets. Arthritis Rheum. (2001) 44(6):1237-1247.
   PubMed Web of Science ®Google Scholar
• SAITO I KT, NAKASHIMA K, UESUGI M, SAITO T: Increased cellular infiltrate in inflammatory synovia of osteoarthritic knees. Osteoarthritis Cartilage (2002) 10(2):156-162.
   PubMed Web of Science ®Google Scholar
• VAN DEN BERG WB, VAN DER KRAAN PM, VAN BEUNINGEN HM: Synovial mediators of cartiliage damage and repair in OA. Brandt KD DM, Lohmander LS (Ed.) Oxford University Press, Oxford, UK (1998):157-167.
   Google Scholar
• SPECTOR TD, HART DJ, NANDRA D et al.: Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum. (1997) 40(4):723-727.
   PubMed Web of Science ®Google Scholar
• SHARIF M, SHEPSTONE L, ELSON CJ, DIEPPE PA, KIRWAN JR: Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann. Rheum. Dis. (2000) 59(1):71-74.
   PubMed Web of Science ®Google Scholar
• AYRAL X, PICKERING EH, WOODWORTH TG, MACKILLOP N, DOUGADOS M: Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis – results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage (2005) 13(5):361-367.
   PubMed Web of Science ®Google Scholar
• SHARIF M, KIRWAN JR, ELSON CJ, GRANELL R, CLARKE S: Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum. (2004) 50(8):2479-2488.
   PubMed Web of Science ®Google Scholar
• PETERSSON IF, BOEGARD T, SVENSSON B, HEINEGARD D, SAXNE T: Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of knee joint. Br. J. Rheum. (1998) 37(1):46-50.
   PubMedGoogle Scholar
• GOLDBERG RL, HUFF JP, LENZ ME, GLICKMAN P, KATZ R, THONAR EJ: Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. (1991) 34(7):799-807.
   PubMed Web of Science ®Google Scholar
• ROMAN-BLAS JA, JIMENEZ SA: NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage (2006) 14(9):839-848.
   PubMed Web of Science ®Google Scholar
• OLIVERIA SA, FELSON DT, REED JI, CIRILLO PA, WALKER AM: Incidence of symptomatic hand, hip and knee osteoarthritis among patients in a health maintenance organisation. Arthritis Rheum. (1995) 38(8):1134-1141.
   PubMed Web of Science ®Google Scholar
• FELSON DT, ZHANG Y: An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. (1998) 41(8):1343-1355.
   PubMed Web of Science ®Google Scholar
• GUCCIONE AA, FELSON DT, ANDERSON JJ et al.: The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am. J. Public Health (1994) 84(3):351-358.
   PubMed Web of Science ®Google Scholar
• JORDAN KM, ARDEN NK, DOHERTY M et al.: EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. (2003) 62(12):1145-1155.
   PubMed Web of Science ®Google Scholar
• ZHANG W, DOHERTY M, ARDEN N et al.: EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. (2005) 64(5):669-681.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. (2000) 43(9):1905-1915.
   PubMed Web of Science ®Google Scholar
• LEE C, STRAUS WL, BALSHAW R, BARLAS S, VOGEL S, SCHNITZER TJ: A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. (2004) 51(5):746-754.
   PubMed Web of Science ®Google Scholar
• BJORDAL JM, LJUNGGREN AE, KLOVNING A, SLØRDAL L: Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritis knee pain: meta-analysis of randomised placebo controlled trials. Br. Med. J. (2004) 329(4):1317-1322.
   PubMed Web of Science ®Google Scholar
• CHAN AT, MANSON JE, ALBERT CM et al.: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation (2006) 113(12):1578-1587.
   PubMed Web of Science ®Google Scholar
• GARCIA RODRIGUEZ LA, HERNANDEZ-DIAZ S: Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology (2001) 12(5):570-576.
   PubMed Web of Science ®Google Scholar
• FORED CM, EJERBLAD E, LINDBLAD P et al.: Acetaminophen, aspirin, and chronic renal failure. N. Engl. J. Med. (2001) 345(25):1801-1808.
   PubMed Web of Science ®Google Scholar
• HAMERMAN D: The biology of osteoarthritis. N. Engl. J. Med. (1989) 320(20):1322-1330.
   PubMed Web of Science ®Google Scholar
• Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 103rd Congress (Oct. 25, 1994).
   Google Scholar
• RUSSELL AS, AGHAZADEH-HABASHI A, JAMALI F: Active ingredient consistency of commercially available glucosamine sulfate products. J. Rheumatol. (2002) 29(11):2407-2409.
   PubMed Web of Science ®Google Scholar
• HUGHES R, CARR A: A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology (2002) 41(3):279-284.
   PubMed Web of Science ®Google Scholar
• MCALINDON T, FORMICA M, LAVALLEY M, LEHMER M, KABBARA K: Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomised double-blind controlled trial. Am. J. Med. (2004) 117(9):643-649.
   PubMed Web of Science ®Google Scholar
• CIBERE J, KOPEC JA, THORNE A et al.: Randomised, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum. (2004) 51(5):738-745.
   PubMed Web of Science ®Google Scholar
• MCALINDON T, FORMICA M, KABBARA K, LAVALLEY M, LEHMER M: Conducting clinical trials over the internet: feasibility study. Br. Med. J. (2003) 327(7413):484-487.
   PubMedGoogle Scholar
• TOWHEED TE, MAXWELL L, ANASTASSIADES TP et al.: Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst. Rev. (2005) (2):CD002946.
   Google Scholar
• NOYSZEWSKI EA, WROBLEWSKI K, DODGE GR et al.: Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfate in articular cartilage explants. Arthritis Rheum. (2001) 44(5):1089-1095.
   PubMed Web of Science ®Google Scholar
• BASSLEER C, ROVATI LC, FRANCHIMONT P: Glucosamine sulfate stimulates proteoglycan production in human chondrocytes in vitro. Osteoarthritis Cartilage (1998) 6(6):427-434.
   PubMed Web of Science ®Google Scholar
• BIGGEE BA, BLINN CM, MCALINDON TE, NUITE M, SILBERT JE: Low levels of human serum glucosamine after ingestion of glucosamine sulfate relative to capability for peripheral effectiveness. Ann. Rheum. Dis. (2006) 65(2):222-226.
   PubMed Web of Science ®Google Scholar
• MROZ PJ, SILBERT JE: Use of 3H-glucosamine and 35S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondroitin sulfate. Arthritis Rheum. (2004) 50(11):3574-3579.
   PubMedGoogle Scholar
• PELLETIER J-P, MARTEL-PELLETIER J, RAYNAULD JP: Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow. Arthritis Res. Ther. (2006) 8(2):206.
   PubMedGoogle Scholar
• GOUZE JN, GOUZE E, POPP MP et al.: Exogenous glucosamine effectively protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Res. Ther. (2006) 8(6):R173.
   PubMed Web of Science ®Google Scholar
• ALTMAN RD, ABRAMSON S, BRUYERE O et al.: Commentary: osteoarthritis of the knee and glucosamine. Osteoarthritis Cartilage (2006) 14(10):963-966.
   PubMed Web of Science ®Google Scholar
• LIANXU C, HONGTI J, CHANGLONG Y: NF-κBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1β-induced and TNF-α-induced chondrocytes. Osteoarthritis Cartilage (2006) 14(4):367-376.
   PubMed Web of Science ®Google Scholar
• UITTERLINDEN EJ, JAHR H, KOEVOET JLM et al.: Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage (2006) 14(3):250-257.
   PubMed Web of Science ®Google Scholar
• LARGO R, ALVAREZ-SORIA MA, DÌEZ-ORTEGO I et al.: Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage (2003) 11(4):290-298.
   PubMed Web of Science ®Google Scholar
• GOUZE JN, BIANCHI A, BECUWE P et al.: Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-κB pathway. FEBS Lett. (2002) 510(3):166-170.
   PubMed Web of Science ®Google Scholar
• DODGE GR, JIMENEZ SA: Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage (2003) 11(6):424-432.
   PubMed Web of Science ®Google Scholar
• LAVERTY S, SANDY JD, CELESTE C et al.: Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum. (2005) 52(1):181-191.
   PubMed Web of Science ®Google Scholar
• ALTMAN RD, CHEUNG H: Glucosamine sulfate on cartilage: lapine study. Arthritis Rheum. (2001) 44(9 Suppl.):1535.
   Web of Science ®Google Scholar
• TIRALOCHE G, GIRARD C, CHOUINARD L et al.: Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum. (2005) 52(4):1118-1128.
   PubMed Web of Science ®Google Scholar
• CHAN PS, CARON JP, ORTH MW: Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. Am. J. Vet. Res. (2005) 66(11):1870-1876.
   PubMed Web of Science ®Google Scholar
• CHAN PS, CARON JP, ROSA GJ, ORTH MW: Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage (2005) 13(5):387-394.
   PubMed Web of Science ®Google Scholar
• HOMANDBERG GA, GUO D, RAY LM, DING L: Mixtures of glucosamine and chondroitin sulfate reverse fibronectin fragment mediated damage to cartilage more effectively than either agent alone. Osteoarthritis Cartilage (2006) 14(8):793-806.
   PubMed Web of Science ®Google Scholar
• PIEPOLI T, ZANELLI T, LETARI O et al.: Glucosamine sulfate inhibits IL-1δ-stimulated gene expression at concentrations found in humans after oral intake. Arthritis Rheum. (2005) 52(9 Suppl.):1326.
   Google Scholar
• SETNIKAR I, ROVATI LC: Absorption, distribution, metabolism and excretion of glucosamine sulfate: a review. Arzneimittelforschung (2001) 51(9):699-725.
   PubMed Web of Science ®Google Scholar
• PERSIANI S, RODA E, ROVATI LC, LOCATELLI M, GIACOVELLI G, RODA A: Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage (2005) 13(12):1041-1049.
   PubMed Web of Science ®Google Scholar
• PERSIANI S, LOCATELLI M, FIORENTINO S, ROVATI LC, RODA A: Absolute bioavailability of glucosamine after administration of crystalline glucosamine sulfate in rats. Osteoarthritis Cartilage (2005) 13(Suppl. A):P161.
   Google Scholar
• PERSIANI S, ROTINI R, TRISOLINO G et al.: Glucosamine plasma and synovial fluid concentrations before and after oral administration of crystalline glucosamine sulfate in knee osteoarthritis patients. Arthritis Rheum. (2005) 52:(9 Suppl.):1342.
   Google Scholar
• JACKSON CG, PLAAS AH, BARNHILL JG, HARRIS CL, CLEGG DO: The pharmacokinetics of oral glucosamine and chondroitin sulfate in humans. American College of Rheumatology meeting (2005) Late breaking abstract L13.
   Google Scholar
• MCALINDON TE, LAVALLEY MP, GULIN JP, FELSON DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA (2000) 283(11):1469-1475.
   PubMed Web of Science ®Google Scholar
• RICHY F, BRUYERE O, ETHGEN O et al.: Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. A comprehensive meta-analysis. Arch. Int. Med. (2003) 163(13):1514-1522.
   PubMed Web of Science ®Google Scholar
• ROVATI LC: The clinical profile of glucosamine sulfate as a selective symptom modifying drug in osteoarthritis: current data and perspectives. Osteoarthritis Cartilage (1997) 5 (Suppl. A):72.
   Google Scholar
• The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis. (CPMP/EWP/784/97) London, July 1998.
   Google Scholar
• REGINSTER JY, DEROISY R, ROVATI LC et al.: Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet (2001) 357(9252):251-256.
   PubMed Web of Science ®Google Scholar
• PAVELKA K, GATTEROVA J, OLEJAROVA M et al.: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch. Intern. Med. (2002) 162(18):2113-2123.
   PubMed Web of Science ®Google Scholar
• MCALINDON T: Glucosamine for osteoarthritis: dawn of a new era? Lancet (2001) 357(9252):247-248.
   PubMed Web of Science ®Google Scholar
• BRANDT KD, MAZZUCA SA: Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs. Arthritis Rheum. (2005) 52(11):3349-3359.
   PubMed Web of Science ®Google Scholar
• BRUYERE O RJ, GIACOVELLI G, BARBETTA B, ROVATI LC, PAVELKA K: Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate. Arthritis Rheum. (2006) 54(11):2339-2341.
   PubMedGoogle Scholar
• BRUYERE O, COMPERE S, ROVATI LC et al.: Five-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis. Arthritis Rheum. (2003) 48(9 Suppl.):89.
   Google Scholar
• PAVELKA K, GATTEROVA J, GIACOVELLI G, OLEJAROVA M, ROVATI LC: Glucosamine sulfate prevents total joint replacement in the long-term follow-up of knee osteoarthritis patients. Arthritis Rheum. (2004) 50:(9 Suppl.):251.
   Google Scholar
• ALTMAN RD, ABADIE E, AVOUAC B et al.: Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis Cartilage (2005) 13(1):13-19.
   PubMed Web of Science ®Google Scholar
• HERRERO-BEAUMONT G, ROMÁN JA, TRABADO MC et al.: Effects of glucosamine sulfate on 6-month control of knee osteoarthritis symptoms versus placebo and acetaminophen: results from the Glucosamine Unum In Die Efficacy (GUIDE) trial. Arthritis Rheum. (2005) 52(9 Suppl.):1203.
   Google Scholar
• NOACK W, FISCHER M, FÖRSTER KK, ROVATI LC, SETNIKAR I: Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage (1994) 2(1):51-59.
   PubMedGoogle Scholar
• MÜLLER-FASSBENDER H, BACH GL, HAASE W, ROVATI LC, SETNIKAR I: Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage (1994) 2(1):61-69.
   PubMedGoogle Scholar
• BRUYERE O, PAVELKA K, ROVATI LC et al.: Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause (2004) 11(2):138-143.
   PubMed Web of Science ®Google Scholar
• CLEGG DO, REDA DJ, HARRIS CL et al.: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. (2006) 358(8):795-808.
   Google Scholar
• BRANDT KD, MAZZUCA SA, CONROZIER T et al.: Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? J. Rheumatol. (2002) 29(6):1308-1320.
   PubMed Web of Science ®Google Scholar
• PAVELKA K, BRUYERE O, ROVATI LC et al.: Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthritis Cartilage (2003) 11(10):730-737.
   PubMed Web of Science ®Google Scholar
• BRUYERE O, HONORE A, ROVATI LC et al.: Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scand. J. Rheumatol. (2002) 31(1):13-16.
   PubMed Web of Science ®Google Scholar
• BRUYERE O, HONORE A, ETHGEN O et al.: Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthritis Cartilage (2003) 11(1):1-5.
   PubMed Web of Science ®Google Scholar
• VARIOUS AUTHORS: Glucosamine and chondroitin sulfate for knee osteoarthritis. N. Engl. J. Med. (2006) 354:2184-2185.
   Google Scholar
• HOUPT JB, MCMILLAN R, WEIN C, PAGET-DELLIO SD: Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J. Rheumatol. (1999) 26(11):2423-2430.
   PubMed Web of Science ®Google Scholar
• HOCHBERG MC: Nutritional supplements for knee osteoarthritis – still no resolution. N. Engl. J. Med. (2006) 354(8):858-860.
   PubMed Web of Science ®Google Scholar
• HOFFER LJ, KAPLAN LN, HAMADEH MJ, GRIGORIU AC, BARON M: Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism (2001) 50(7):767-770.
   PubMed Web of Science ®Google Scholar
• CORDOBA F, NIMNI ME: Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. Osteoarthritis Cartilage (2003) 11(3):228-230.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, ROVATI LC, HENROTIN Y et al.: Glucosamine sulphate and osteoarthritis. Lancet (2001) 357(9252):1618.
   Google Scholar
• BARON AD, ZHU JS, ZHU JH et al.: Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. J. Clin. Invest. (1995) 96(6):2792-2801.
   PubMed Web of Science ®Google Scholar
• MONAUNI T, ZENTI MG, CRETTI A et al.: Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes (2000) 49(6):926-935.
   PubMed Web of Science ®Google Scholar
• POUWELS MJ, JACOBS JR, SPAN PN et al.: Short-term glucosamine infusion does not affect insulin sensitivity in humans. J. Clin. Endocrinol. Metab. (2001) 86(5):2099-2103.
   PubMed Web of Science ®Google Scholar
• TANNIS AJ, BARBAN J, CONQUER JA: Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage (2004) 12(6):506-511.
   PubMed Web of Science ®Google Scholar
• SCROGGIE DA, ALBRIGHT A, HARRIS M: The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with Type 2 daibetes mellitus. A placebo-controlled, double-blinded, randomized clinical trial. Arch. Int. Med. (2003) 163(13):1587-1590.
   PubMed Web of Science ®Google Scholar
• ROVATI LC, ANNEFELD M, GIACOVELLI G, SCHMID K, SETNIKAR I: Glucosamine in osteoarthritis. Lancet (1999) 354(9176):1640.
   PubMedGoogle Scholar
• ANDERSON JW NR, BORZELLECA JF: Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem. Toxicol. (2005) 43(2):187-201.
   PubMed Web of Science ®Google Scholar